Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
Developing and validating innovative technologies for improved handling of biospecimens in cancer research and care, to enhance quality and accelerate progress.
Browse similar grants
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: April 4, 2025 | October 3, 2025 | December 9, 2025 (final closing date)
Funding Amounts: Up to $300,000 per year (direct costs), max 3 years; total program funding $300,000; ~2 awards expected.
Summary: Supports advanced development and validation of emerging biospecimen science technologies to improve sample quality and handling for cancer research or care.
Key Information: Clinical trials are not allowed; projects must focus on technology development/validation, not hypothesis-driven research.
Description
This opportunity, offered by the National Cancer Institute (NCI) under the NIH, supports exploratory research projects focused on the advanced development and rigorous validation of emerging technologies that improve the quality and handling of biospecimens used for cancer research and clinical care. The goal is to accelerate and enhance cancer research by supporting tools, devices, assays, and associated methods for the collection, processing, preservation, or storage of cancer-relevant biospecimens and their derivatives. Projects must demonstrate that major feasibility gaps have already been overcome and require further development and validation to encourage adoption by the research community.
Technologies should offer substantial improvements over current methods or add qualitatively new research capabilities, with a focus on quantitative performance measures. Projects solely applying existing technologies or pursuing biological/clinical hypotheses without substantial technical innovation are not eligible.
